| Autor: |
Salinas-Jazmín, Nohemí, Estrada-Parra, Sergio, Becerril-García, Miguel Angel, Limón-Flores, Alberto Yairh, Vázquez-Leyva, Said, Medina-Rivero, Emilio, Pavón, Lenin, Velasco-Velázquez, Marco Antonio, Pérez-Tapia, Sonia Mayra |
| Předmět: |
|
| Zdroj: |
Journal of Immunology Research; 4/23/2015, Vol. 2015, p1-9, 9p, 1 Chart, 5 Graphs |
| Abstrakt: |
Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that are released on disruption of peripheral blood leukocytes from healthy donors. DLEs improve clinical responses in infections, allergies, cancer, and immunodeficiencies. Transferon is a human DLE that has been registered as a hemoderivate by Mexican health authorities and commercialized nationally. To develop an animal model that could be used routinely as a quality control assay for Transferon, we standardized and validated a murine model of cutaneous HSV-1 infection. Using this model, we evaluated the activity of 27 Transferon batches. All batches improved the survival of HSV-1-infected mice, wherein average survival rose from 20.9% in control mice to 59.6% in Transferon-treated mice. The activity of Transferon correlated with increased serum levels of IFN-γ and reduced IL-6 and TNF-α concentrations. Our results demonstrate that (i) this mouse model of cutaneous herpes can be used to examine the activity of DLEs, such as Transferon; (ii) the assay can be used as a routine test for batch release; (iii) Transferon is produced with high homogeneity between batches; (iv) Transferon does not have direct virucidal, cytoprotective, or antireplicative effects; and (v) the protective effect of Transferon in vivo correlates with changes in serum cytokines. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
